After bagging $200M-plus in 2019, Passage Bio guns for $125M IPO

FierceBiotech | February 04, 2020

Despite pulling off two megarounds in 2019, Passage Bio is returning to the funding well—but this time, it’s going public. The company filed for a $125 million IPO, which will bankroll the development of its three lead gene therapy programs in dementia, Krabbe disease and rare childhood disease GM1 gangliosidosis.  Those programs were among five that Passage picked up in its partnership with the University of Pennsylvania’s Gene Therapy Program in February 2019. At the same time, the Philadelphia-based biotech reeled in a $115.5 million series A round to bankroll the development of those programs, all of which target rare, monogenic central nervous system (CNS) diseases.

Spotlight

With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain. This insightful infographic breaks it out for you.  It includes FDA-approved abuse-deterrent formulations (ADFs) and technologies, which trial sponsors are leading the pack, and a look at the state of the ADF pipeline.

Spotlight

With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain. This insightful infographic breaks it out for you.  It includes FDA-approved abuse-deterrent formulations (ADFs) and technologies, which trial sponsors are leading the pack, and a look at the state of the ADF pipeline.

Related News

Amagma Therapeutics Announces Strategic Partnership with Innovent Biologics in Inflammatory Diseases

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The collaboration will allow Innovent to access novel, first-in-class molecules for inflammatory disorders with little to no existing treatment options. Amagma will secure clinical manufacturing for its lead programs and gain a proven regional partner with extensive expertise in protein engineering and manufacturing. Under the terms of the agreement, Innovent will be responsible for the manufacture of the three programs through a Phase 2 study and, if Innovent exercises its option, research, development, and commercialization of each program in Greater China. Amagma will continue to be responsible for global research and development prior to option exercise and ex-China research, development and commercialization thereafter. Amagma is eligible to receive development, approval, and commercial milestones if Innovent exercises the options. Amagma may also receive royalties on net sales of any commercial products in the territory. “This transaction highlights an innovative approach to securing manufacturing expertise in exchange for insights into novel disease biology from our SEIZMIC™ platform. Innovent has demonstrated themselves to be an excellent partner with robust capabilities and strong execution. We look forward to working with Innovent to potentially advance these novel therapies.” Tillman Gerngross, Ph.D., Co-founder, Chairman, Amagma Therapeutics About Amagma Therapeutics Amagma Therapeutics is developing precision antibody therapeutics against inflammatory diseases which have proven to be intractable by other approaches. A number of these serious illnesses are driven by overactive extracellular proteases which can compromise organ function and fuel inflammation. The Company’s SEIZMIC proprietary discovery platform enables screening and development of highly selective antibodies that can inhibit dysfunctional enzyme activity. Amagma was founded in 2019 by serial entrepreneur scientists Leonard Zon and Tillman Gerngross. Amagma is based in Waltham, MA.

Read More

CELL AND GENE THERAPY

IsoPlexis Acquired a Large Portfolio of DNA and RNA Sequencing to Enable Integrated Single-Cell Sequencing and Proteomic Solutions

IsoPlexis | May 26, 2021

IsoPlexis, the leader in functional single-cell proteomics, announced today the acquisition of a large intellectual property portfolio containing 86 patents related to DNA and RNA sequencing. These nucleic acids and sequencing technologies will be immediately integrated with IsoPlexis' single-cell proteomics platforms, enabling a variety of next-generation tests that include numerous 'omic modalities from every single cell. This is the next step in the company's roadmap, enabling researchers to make far earlier connections in their genomic studies, straight to the proteome, which determines each organism's in vivo dynamic biology. The acquired assets will allow IsoPlexis' proprietary proteomics technologies to be integrated with newer proprietary sequencing-based technologies. The asset acquisition adds to IsoPlexis' ongoing efforts to assist its customers in more effectively simplifying complex biology to accelerate the creation of more personalized and curative advanced medicines from bench to bedside. Isoplexis' growing patent portfolio of 153 total patents filed and issued globally will now include sequencing methodologies, allowing for a new level of resolution into the connections between the genome and the proteome of cancer immunology, cell and gene therapy, neurological disease, and other areas. IsoPlexis' proprietary functional proteomics platform is the first to fully characterize and link cellular function to patient outcomes, treatment response, or disease progression using both proteomics and single-cell biology. The single-cell proteomics platform from IsoPlexis, which comprises instruments, chip consumables, and software, offers an end-to-end solution for providing a more complete view of protein function at the cellular level. The platform has been quickly embraced by the top 15 global biopharmaceutical companies in terms of revenue, as well as over half of the comprehensive cancer centers in the United States, to develop more durable therapeutics, overcome therapeutic resistance, and predict patient responses for advanced immunotherapies, cell therapies, gene therapies, vaccines, and regenerative medicines. ABOUT ISOPLEXIS IsoPlexis is a life science technology company that develops solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect to in vivo biology more directly and develop more precise and personalized therapies. Our integrated systems, which were named top innovation or design by Scientist Magazine, Fierce, BIG Innovation, Red Dot, and a variety of other magazines, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been used by researchers all over the world, including the top 15 pharmaceutical companies in the world and 45% of comprehensive cancer centers in the United States.

Read More

INDUSTRIAL IMPACT

ADM Further Expands Microbial Science and Technology Innovation Capabilities with Investment in Precision Fermentation Leader Acies Bio

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re propelling growth opportunities by working with innovators who appreciate our unique combination of expertise, capacity and access to feedstocks. Now, by investing to become a minority owner in Acies Bio, we’re opening up the door to new collaboration with an innovative, complementary business to meet the growing demand for products developed via microbial fermentation.” Ian Pinner, ADM chief strategy and innovation officer. Founded in 2006, Acies Bio develops innovative, proprietary microbial and synthetic biology-based platforms and technologies and also offers contract R&D services in microbial strain engineering and fermentation for customers in key growth segments, including sustainable agriculture, functional foods and bio-based industrial chemicals. “Acies Bio’s core mission is to use the nearly unlimited power of microbial diversity to drive disruptive innovation and help create a more sustainable bio-based future,” said Enej Kuščer, Acies Bio's co-founder and director. “This strategic partnership with ADM will allow Acies Bio to expand and accelerate the development of our platform technologies, which aim to replace synthetic chemicals and the often carbon-intensive production currently used in food and agriculture with microbial, bio-based products.” “This investment from ADM will also allow Acies Bio to expand our infrastructure and increase the high-throughput capabilities of our SmartRoute platform, which will allow faster development of new technologies and products,” said Štefan Fujs, Acies Bio's co-founder and director. “This will speed-up the internal pipeline and also help us deliver more quality services to our partners and collaborators.” ADM’s investment in Acies Bio is being made through ADM Ventures, the company’s corporate venture capital arm. ADM Ventures invests in cutting-edge start-ups with disruptive technologies across three key areas: human nutrition, animal nutrition and sustainability. ADM Ventures also seeks startups that utilize ADM’s assets and feedstocks to produce sustainable materials, in addition to technologies that enhance the effectiveness or efficiency of ADM’s operations. About Acies Bio Acies Bio is a leading European microbial biotechnology company that develops new bioproducts and sustainable production processes for diverse industrial sectors, including pharma, food/feed, agricultural, and industrial biotechnology. With an emphasis on sustainability and using Acies Bio’s unique SmartRoute microbial platform, including synthetic biology and strain engineering, high-throughput screening, precision bioprocess and downstream development, the company has successfully developed and scaled numerous innovative products and precision fermentation technologies with industrial partners worldwide. About ADM At ADM, we unlock the power of nature to provide access to nutrition worldwide. With industry-advancing innovations, a complete portfolio of ingredients and solutions to meet any taste, and a commitment to sustainability, we give customers an edge in solving the nutritional challenges of today and tomorrow. We’re a global leader in human and animal nutrition and the world’s premier agricultural origination and processing company. Our breadth, depth, insights, facilities and logistical expertise give us unparalleled capabilities to meet needs for food, beverages, health and wellness, and more. From the seed of the idea to the outcome of the solution, we enrich the quality of life the world over.

Read More